Research Chemical Designation & Liability

Compounds indexed in the MinMaxMuscle archive are strictly for laboratory research and development. They are NOT approved for human consumption. Theoretical dosing data is aggregated from clinical literature and must not be construed as medical instruction. Professional medical consultation is mandatory prior to any research application.

Full Disclaimer
Archive Identifier

FGF-21

Metabolic & Weight Loss

Molecular Dossier

  • Rank Index: 61
  • Status: Phase 2 Clinical
  • What does this mean?
  • Molecular Structure: MW: 18,646 Da | 181 AA | FGFR1c/KLB co-receptor agonist

About FGF-21

Fibroblast growth factor 21 is a metabolic hormone produced primarily by the liver. Activates FGFR1/KLB complex to improve insulin sensitivity, reduce liver fat, increase adiponectin, and promote fat oxidation. Multiple pharmaceutical analogues (pegbelfermin, efruxifermin) in Phase 2/3 trials for NASH/MAFLD and dyslipidemia.

Clinical Focus

Insulin Sensitization, Hepatic Fat Reduction, Adiponectin Elevation

Archival Aliases

FGF21, Fibroblast Growth Factor 21, hFGF-21

Frequently Asked Questions

Clinical Data Matrix

Parameter Clinical Value
Molecular Weight MW: 18,646 Da | 181 AA | FGFR1c/KLB co-receptor agonist
Primary Pathway Metabolic & Weight Loss
Research Phase Phase 2 Clinical

Clinical Pros

  • Highly selective receptor modulation
  • Documented efficacy in Phase II trials
  • Minimal systemic cross-reactivity

Research Limitations

  • Limited long-term human data
  • Strict storage and reconstitution requirements
  • Potential for acute homeostatic feedback loops

Community Discussion

Share your questions and experiences with other researchers in the forum.

Discuss in Forum

Clinical Reference Nodes

[REF 1] pubmed.ncbi.nlm.nih.gov
[REF 2] pubmed.ncbi.nlm.nih.gov
[REF 3] pubmed.ncbi.nlm.nih.gov

Data Verified: 2026-04-14

Synergistic Matrix